TrialClinical cancer research : an official journal of the American Association for Cancer Research2023

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression.

Stephanie Lheureux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.